$100m of diabetes R&D in China

Danish drug maker Novo Nordisk has announced plans to invest $100 million (£62 million) in its R&D site in Beijing, China. The move will create 130–200 new research jobs.

Novo Nordisk was one of the first big pharma companies to establish at R&D outpost in China, making the move in 1997. The company currently employs 130 researchers at the Beijing site, part of its 3000 strong workforce across all business areas in the country.

The company specialises in insulin products for the treatment of diabetes.